Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators.

N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.

2.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

3.

Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.

Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittes J, Meyer CJ.

J Card Fail. 2014 Dec;20(12):953-8. doi: 10.1016/j.cardfail.2014.10.001. Epub 2014 Oct 13.

4.

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM.

Am J Nephrol. 2013;37(3):212-22. doi: 10.1159/000346948. Epub 2013 Feb 28.

5.

Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.

Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, Packham D, Vaziri ND, Ward KW, Warnock DG, Meyer CJ.

Am J Nephrol. 2014;39(6):499-508. doi: 10.1159/000362906. Epub 2014 Jun 3.

6.

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D.

Nephrol Dial Transplant. 2013 Nov;28(11):2841-50. doi: 10.1093/ndt/gft445.

PMID:
24169612
7.

Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis.

Warnock DG, Hebbar S, Bargman J, Burkart J, Davies S, Finkelstein FO, Mehrotra R, Ronco C, Teitelbaum I, Urakpo K, Chertow GM.

Contrib Nephrol. 2012;178:157-63. doi: 10.1159/000337837. Epub 2012 May 25. Review.

PMID:
22652731
8.

Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.

Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, Warnock DG.

Am J Nephrol. 2011;33(5):469-76. doi: 10.1159/000327599. Epub 2011 Apr 21.

9.

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators.

Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24.

PMID:
24795251
10.
11.

Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

McMahon GM, Forman JP.

N Engl J Med. 2011 Nov 3;365(18):1746; author reply 1746-7. doi: 10.1056/NEJMc1110239. No abstract available.

PMID:
22047581
12.

Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

Upadhyay A, Sarnak MJ, Levey AS.

N Engl J Med. 2011 Nov 3;365(18):1746; author reply 1746-7. doi: 10.1056/NEJMc1110239. No abstract available.

PMID:
22047580
13.

Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

Rogacev KS, Bittenbring JT, Fliser D.

N Engl J Med. 2011 Nov 3;365(18):1745-6; author reply 1746-7. doi: 10.1056/NEJMc1110239. No abstract available.

PMID:
22047579
14.

Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

Van Laecke S, Vanholder R.

N Engl J Med. 2011 Nov 3;365(18):1745; author reply 1746-7. doi: 10.1056/NEJMc1110239. No abstract available.

15.

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D.

Diabetes Obes Metab. 2008 Jul;10(7):545-55. doi: 10.1111/j.1463-1326.2008.00914.x. Epub 2008 Jun 1.

PMID:
18518892
16.

Strict blood-pressure control and progression of renal failure in children.

ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.

N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.

17.

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T.

Intern Med. 2011;50(10):1081-7. Epub 2011 May 1.

19.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

20.

Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus.

Schwartz SL, Rendell M, Ahmann AJ, Thomas A, Arauz-Pacheco CJ, Welles BR.

Clin Ther. 2008 Jun;30(6):1081-8. doi: 10.1016/j.clinthera.2008.05.021.

PMID:
18640464

Supplemental Content

Support Center